BREA, Calif. & TOKYO--(BUSINESS WIRE)--Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today ...
BREA, Calif., Sept. 10, 2025 /PRNewswire/ -- Beckman Coulter Diagnostics, a Danaher company and a leader in global clinical diagnostics innovation, today launched the industry's first fully automated ...
BREA, Calif. & TOKYO--(BUSINESS WIRE)--Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today ...
(RTTNews) - Beckman Coulter Diagnostics, the clinical diagnostics unit of science and technology firm Danaher Corp. (DHR), announced Monday that the new DxC 500i Clinical Analyzer received 510(k) ...
"Our new SARS-CoV-2 IgM assay provides information about an individual's immune status with a positive predictive value of 95.5% in a population with disease incidence as low as 3%," said Julie Sawyer ...
Brea-based diagnostic testing machine and supply maker Beckman Coulter Inc. could get some company within parent Danaher Corp.’s life sciences and diagnostics unit. Johnson & Johnson, the New ...
Beckman Coulter, a clinical diagnostics leader, today announced the launch of its Access SARS-CoV-2 Immunoglobulin M (IgM) assay in countries accepting the CE Mark. The new IgM antibody test ...
Collaboration Builds upon Fujirebio Expertise in Neurodegenerative Disease Assays and Beckman Coulter's High Sensitivity, High Throughput, Global Installed Base of Access Family of Immunoassay ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results